Welcome to Flow Pharma Inc.

Page Loading...

Our Biomedicines

FlowVax BreastCA

FlowVax BreastCA is being designed to treat a wide range of breast cancers.

Flow Pharma published two papers in 2023 looking at the tumor associated antigen survivin which is present on multiple tumors including breast cancer:

  1. A mouse version of FlowVax BreastCA targeting survivin was effective at slowing the growth of triple negative breast cancer.
  2. FlowVax Pharma researchers found that women with luminal breast cancer presenting for surgery had survivin expressed on tumor tissue but not on adjacent normal breast tissue.


  • Under Development, FDA Approval Required.
  • Available On-Demand bio-medicine targeting tumor-associated antigens.
  • Will work for many breast cancer patients.
  • Delivered through intranodal injection
  • Engineered with next-generation sequencing and artificial intelligence.


  • Pre-Clinical Feasibility
  • Gene Sequencing Clinical Study
  • Phase I Clinical Study


What is Breast Cancer?

Breast cancer cells

Breast cancer is an abnormal growth disease that most commonly presents as a lump that feels different from the rest of the breast tissue. More than 80% of cases are discovered when a person detects such a lump with the fingertips. The earliest breast cancers, however, are detected by a mammogram.

A scanning electron microscopic 3D-enhanced NIH image of cancer cells and lamellipodia spike processes on a cellular tissue surface. Credit: National Institutes of Health/Department of Health and Human Services

Read More.

Want to learn more about the science behind the solution?

View Resources